finder CA
CA
AU
US
NZ
UK
SG
More

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Codiak BioSciences stock in Canada

Own Codiak BioSciences shares in just a few minutes.

Jing Jun Ma
Jing Jun Ma

Posted

Fact checked
Compare brokers buy Codiak BioSciences (CDAK)

Codiak BioSciences, Inc is a biotechnology business based in the US. Codiak BioSciences shares (CDAK.US) are listed on the NASDAQ and all prices are listed in US Dollars. Codiak BioSciences employs 101 staff and has a trailing 12-month revenue of around $1.4 million.

How to buy shares in Codiak BioSciences

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: CDAK in this case.
  5. Research Codiak BioSciences shares. The platform should provide the latest information available.
  6. Buy your Codiak BioSciences shares. It's that simple.

What's in this guide?

  1. Can I buy shares in Codiak BioSciences?
  2. Codiak BioSciences shares summary
  3. Compare share dealing platforms
  4. Is Codiak BioSciences stock a buy or sell?
  5. Can I short Codiak BioSciences shares?
  6. Codiak BioSciences's financials
  7. Does Codiak BioSciences pay a dividend?
  8. Other common questions

Codiak BioSciences share price

Use our graph to track the performance of CDAK stocks over time.

Codiak BioSciences shares at a glance

Information last updated 2021-01-23.
Latest market close$N/A
52-week range$7.9 - $37.85
50-day moving average $23.2183
200-day moving average $16.3378
Wall St. target price$35
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Compare online trading platforms

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost
Wealthsimple Trade
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $25 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Go to site
More Info
Questrade
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, IPOs, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Go to site
More Info
Interactive Brokers
Interactive Brokers
Stocks, Bonds, Options, Mutual Funds, ETFs, Currencies, Futures, Precious Metals
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Go to site
More Info
loading

Compare up to 4 providers

Name Product Minimum deposit to invest Funding methods Management fee Available asset types
Wealthsimple Invest
Wealthsimple Invest
$1
Direct deposit, Bank transfer
0.40% - 0.50%
Stocks, Bonds, ETFs, Commodities
Get a $50 bonus when you open and fund your first Wealthsimple Invest account with a minimum initial deposit of at least $500. Trade and Cash accounts are not eligible.
Go to site
More Info
CI Direct Investing (formerly WealthBar)
CI Direct Investing (formerly WealthBar)
$1,000
Direct deposit, Bank transfer
0.35% - 0.60%
Mutual Funds, ETFs
CI Direct Investing offers access to an exclusive and personalized investment portfolio. Get up to $10,000 managed free for a year when you sign up for your first CI Direct Investing account and fund your account.
Go to site
More Info
Justwealth
Justwealth
$5,000
Direct deposit, Bank transfer, Automatic bank withdrawals
0.50%
ETFs
Receive a cash bonus of $50.00-$225.00 when you open a new Justwealth account. RESP accounts require no minimum deposit to begin investing.
Go to site
More Info
Moka
Moka
$0
Automatic bank withdrawals
$3/month
ETFs
The Moka app rounds up every purchase you make to the nearest dollar and invests the spare change into low-cost exchange-traded funds (ETFs).
Go to site
More Info
loading

Compare up to 4 providers

Name Product Minimum Opening Deposit Commission Available Markets Platforms
Forex.com
Forex.com
US$100
Minimum US$25
Forex
Metals
Commodities
Indices
Shares
Forex.com Desktop, Forex.com Web Trading, Forex.com Mobile Trading, MetaTrader 4
CFDs are leveraged products which involves greater risk than using cash resources only. You could lose all or more of your initial investment. Trade 80+ currency pairs and 220+ CFDs in equities, commodities and indices on Forex.com.
Go to site
More Info
loading

Compare up to 4 providers

Is it a good time to buy Codiak BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Codiak BioSciences financials

Revenue TTM USD$1.4 million
Gross profit TTM USD$-59,113,000
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$499.2 million

TTM: trailing 12 months

How to short and sell Codiak BioSciences shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "CDAK.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 701,693 Codiak BioSciences shares held short by investors – that's known as Codiak BioSciences's "short interest". This figure is 20.8% up from 581,092 last month.

There are a few different ways that this level of interest in shorting Codiak BioSciences shares can be evaluated.

Codiak BioSciences's "short interest ratio" (SIR)

Codiak BioSciences's "short interest ratio" (SIR) is the quantity of Codiak BioSciences shares currently shorted divided by the average quantity of Codiak BioSciences shares traded daily (recently around 407961.04651163). Codiak BioSciences's SIR currently stands at 1.72. In other words for every 100,000 Codiak BioSciences shares traded daily on the market, roughly 1720 shares are currently held short.

However Codiak BioSciences's short interest can also be evaluated against the total number of Codiak BioSciences shares, or, against the total number of tradable Codiak BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Codiak BioSciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Codiak BioSciences shares in existence, roughly 40 shares are currently held short) or 0.0733% of the tradable shares (for every 100,000 tradable Codiak BioSciences shares, roughly 73 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Codiak BioSciences.

Find out more about how you can short Codiak BioSciences stock.

Codiak BioSciences share dividends

We're not expecting Codiak BioSciences to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Codiak BioSciences overview

Codiak BioSciences, Inc. is harnessing exosomes?natural intercellular messengers?to pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders, and rare diseases. Codiak BioSciences, Inc. has a strategic collaboration with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of exoVACC vaccine platform for SARS-CoV-2 and human immunodeficiency virus. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site